


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Intel Patent Application of:

IKEDA et al.

Serial No.: 10/713,008

Filed: November 17, 2003

)
)
)
)
) Art Unit: Unassigned

)
) Examiner: Unassigned
)

For: METHODS FOR PROLIFERATING TERMINAL DIFFERENTIATED CELLS AND
RECOMBINANT VECTORS THEREFOR

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

The following are enclosed for consideration in the above-identified application:


	FEE
<input type="checkbox"/> Response to Notice to File Missing Parts	\$
<input checked="" type="checkbox"/> Information Disclosure Statement	\$
<input type="checkbox"/> Declaration: <input type="checkbox"/> Original; <input type="checkbox"/> Supplemental	\$
<input type="checkbox"/> Submission of Formal Drawings	\$
<input type="checkbox"/> Informal Drawings: ___ Sheets ___ Figures	\$
<input type="checkbox"/> Supplemental Information Disclosure Statement, Form PTO SB/08A, copy of International Search Report, and three (3) references	\$
<input type="checkbox"/> Amendment: <input type="checkbox"/> Preliminary; <input type="checkbox"/> § 116; <input type="checkbox"/> § 312; <input type="checkbox"/> Other	\$
<input type="checkbox"/> Request for Extension of Time <input type="checkbox"/> 2 month(s)	\$
<input type="checkbox"/> Issue Fee: <input type="checkbox"/> Part B - Issue Fee Transmittal <input type="checkbox"/> Part C - Charge to Deposit Account	\$
<input type="checkbox"/> Notice of Appeal	\$
<input type="checkbox"/> Appeal Brief	\$
<input type="checkbox"/> Request for Oral Hearing	\$
<input type="checkbox"/> Reply Brief	\$
<input type="checkbox"/> Terminal Disclaimer	\$
<input type="checkbox"/> An additional claim fee is required, and is calculated as shown below	\$
TOTAL FEES BEING SUBMITTED	\$0

	Claims Remaining	Claims Paid For	Extra	Rate	Fee
Total Claims			0	x \$18.00	\$
Independent Claims			0	x \$86.00	\$
Multiple Dependent Claims (if applicable)				\$	\$
TOTAL EXCESS CLAIMS FEE					\$
SMALL ENTITY TOTAL (if applicable)					\$.00

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and § 1.17 associated with this communication or credit any overpayment to the deposit account of Hunton & Williams, Deposit Account Number 50-0206.

Respectfully submitted,

Date: March 3, 2004

By: 
David H. Milligan
Registration No. 42,893

HUNTON & WILLIAMS LLP
Intellectual Property Department
1900 K Street, N.W.
Suite 1200
Washington, D.C. 20006-1109
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:) Attorney Docket No. 64517.000002
)
IKEDA et al.) Art Unit: Unassigned
)
Application No.: 10/713,008) Examiner: Unassigned
)
Filed: November 17, 2003)
)



For: METHODS FOR PROLIFERATING TERMINAL DIFFERENTIATED CELLS AND
RECOMBINANT VECTORS THEREFOR

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicants respectfully request consideration of the references listed on the attached Form PTO/SB/08A. Enclosed please find copies of the references listed on the attached Form PTO/SB/08A for consideration.

Applicants respectfully point out that the submission of the listed documents in this Information Disclosure Statement is not an admission that it is a prior art or that it is material to patentability of any claims of the application. Also, the submission of this Information Disclosure Statement is not an indication that a search has been made.


Applicants respectfully request that the Examiner consider the references cited on the Form PTO/SB/08A and that the Examiner indicate that the references have been considered in this application by returning a copy of the Form PTO/SB/08A with the Examiner's initials in the left column per MPEP 609.

This IDS is submitted prior to the issuance of a first Office Action on the merits; therefore, it is believed that no fees are required in connection therewith. If any fees are

necessitated by the filing of this Information Disclosure Statement, please charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,
HUNTON & WILLIAMS LLP


By:



David H. Milligan
Registration No. 42,893

Hunton & Williams, LLP
1900 K Street, N.W., Suite 1200
Washington, D.C. 20006-1109
(202) 955-1500 (Telephone)
(202) 778-2201 (Facsimile)

Dated: March 4, 2004

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 64517.000002		SERIAL NO.: 10/713,008	
<div style="text-align: center;">  </div> LIST OF MATERIALS CITED BY APPLICANT (Attach several sheets if necessary)				INVENTOR'S NAME: IKEDA, <i>et al.</i>		EXAMINER: Not Assigned	
				FILING DATE: November 17, 2003		GROUP ART UNIT: Not Assigned	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	1.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	2.						
	3.						
OTHER MATERIALS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	4.	Gavin BROOKS et al., Arresting developments in the cardiac myocyte cell cycle: Role of cyclin-dependent kinase inhibitors, Cardiovascular Research (1997), Vol. 39, pp. 301-311					
	5.	Charles J. SHERR et al., CDK inhibitors: positive and negative regulators of G1-phase progression, GENES & DEVELOPMENT, (1999), Vol. 13, pp. 1501-1512					
	6.						
	7.						
	8.						
	9.						
	10.						
	11.						
	12.						
	13.						
	14.						
	15.						
	16.						
	17.						
	18.						
	19.						
EXAMINER		DATE CONSIDERED					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							